Top Markets
#1 ADO Protocol ADO Protocol +194.43%
#2 Islamic Coin Islamic Coin +155.35%
#3 GoPlus Security GoPlus Security +40.15%
#4 GAIB AID GAIB AID +24.67%
#5 Victoria VR Victoria VR +19.28%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.36%
#7 Wrapped NXM Wrapped NXM +15.19%
#8 Verus Coin Verus Coin +13.65%
#9 Pons Pons +12.72%
#10 o1.exchange o1.exchange +11.86%
Coin of the day
ADO Protocol ADO Protocol
Innstillinger
Språk
NORSK
Valuta
USD
Tema
PJSC Pharmsynthez PJSC Pharmsynthez

PJSC Pharmsynthez

LIFE
Rangering i aksjer #34298
PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation,... PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation, production, and supply of both proprietary (officinal) and generic active pharmaceutical ingredients across Russia and the Commonwealth of Independent States (CIS). Its portfolio of branded medicines includes Neovir, Segidrin, Fenasid, and Penkrofton, which are employed in critical therapeutic areas such as oncology, gynecology, the management of immune deficiencies, and tuberculosis. Public Joint-Stock Company Pharmsynthez has also established a collaboration with HiFiBiO Therapeutics Inks for the clinical advancement and market introduction of their SARS-CoV-2 neutralizing antibody within Russia. The company, which began operations in 1996, is headquartered in St. Petersburg, Russia.
Aksjekurs
$0.019597
Markedsverdi
$5.90M
Endring (1 dag)
-5.92%
Endring (1 år)
-54.49%
Land
RU
Handel PJSC Pharmsynthez (LIFE)

Kategori

Healthcare
Inntekter for PJSC Pharmsynthez (LIFE)
Inntekter i 2026 TTM: 0
Ifølge PJSC Pharmsynthez sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for PJSC Pharmsynthez fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE